A multicenter , randomized, double-blind ,chronic dosing , parallel-group, placebo controlled Phase 3 study to evaluate the efficacy and safety of Benralizumab 100mg in Patients with moderate to very severe chronic obstructive pulmonary disease (COPD) with a history of frequent COPD exacerbations and elevated peripheral blood eosinophils (RESOLUTE) - D3251C00014